Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3510 Target Snapshot

Carbonic anhydrase 14 · SINGLE PROTEIN · Homo sapiens

929Compounds
101Assays
31Approved Drugs
1,131.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9ULX7. Use UniProt Q9ULX7 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9ULX7 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Carbonic anhydrase 14 as ChEMBL target CHEMBL3510, mapped to UniProt Q9ULX7. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Carbonic anhydrase 14
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3510
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9ULX7
Carbonic anhydrase 14
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Carbonic anhydrase 14 is the right protein anchor across sources, using UniProt Q9ULX7 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCarbonic anhydrase 14
UniProt AccessionQ9ULX7
Component TypeProtein
Sequence Length337 aa

Carbonic anhydrase 14

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Carbonic anhydrase 14, mapped to UniProt Q9ULX7. Sequence length is 337 aa.

Mapped IDQ9ULX7
Review nameCarbonic anhydrase 14
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

31
Approved
8
Phase III
8
Phase II
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC5039.0
KI732.0
KD360.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4562296 11.0 Kd 0.01 Preclinical
CHEMBL4553519 11.0 Kd 0.01 Preclinical
CHEMBL4543024 11.0 Kd 0.01 Preclinical
CHEMBL4539233 11.0 Kd 0.01 Preclinical
CHEMBL4475073 11.0 Kd 0.01 Preclinical
CHEMBL4470832 11.0 Kd 0.01 Preclinical
CHEMBL4466140 11.0 Kd 0.01 Preclinical
CHEMBL4456851 11.0 Kd 0.01 Preclinical
CHEMBL4437818 11.0 Kd 0.01 Preclinical
CHEMBL4170371 11.0 Kd 0.01 Preclinical
Distribution

pChEMBL Value Distribution

104
5.0
35
5.5
121
6.0
72
6.5
240
7.0
103
7.5
137
8.0
47
8.5
42
9.0
14
9.5
pChEMBL
Approved Drugs

Approved Drugs

LACOSAMIDE
CHEMBL58323
Approved 2008
NILOTINIB
CHEMBL255863
Approved 2007
ZOLEDRONIC ACID
CHEMBL4303669
Approved 2001
VALDECOXIB
CHEMBL865
Approved 2001
IMATINIB
CHEMBL941
Approved 2001
BRINZOLAMIDE
CHEMBL220491
Approved 1998
CELECOXIB
CHEMBL118
Approved 1998
DORZOLAMIDE
CHEMBL218490
Approved 1994
FAMOTIDINE
CHEMBL902
Approved 1986
INDAPAMIDE
CHEMBL406
Approved 1983
ETHOXZOLAMIDE
CHEMBL18
Approved 1982
FUROSEMIDE
CHEMBL35
Approved 1966
METHAZOLAMIDE
CHEMBL19
Approved 1959
DICHLORPHENAMIDE
CHEMBL17
Approved 1958
ACETAZOLAMIDE
CHEMBL20
Approved 1953
Assay Landscape

Assay Landscape

101
Total Assays
725
Tested Compounds
2
Assay Types
Binding — 99 assays, 725 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 87 606 6.9
assay format 12 119 8.6
ADME — 2 assays, 20 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 20 7.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine